Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1471)	8/31/2015 12:15:54 PM
From: Mirror Image	Read Replies (2) \| Respond to of 2026

Btw, I read that article. Not that I'm complaining, but doesn't the title of it mislead, in regards to Apricus? There is no BIG FDA decision in regards to RayVa - is there? Other than maybe allow or not allow a Phase 2B on it? Further, is there confirmation of that decision happening in September? And if there is, would that be considered BIG? Maybe for us it is ( current Apricus Shareholders ). As far as I knew - the results of the Phase 2A on RayVa were going to made public in September. Not that it's a small thing for Apricus. But I didn't know of a pending BIG FDA decision that was going to be made in September.